|
Jerini AG announced today the signing of a research collaboration agreement with Baxter AG to develop a novel synthetic molecule for use in affinity purification of a therapeutic protein
BERLIN, Germany | January 10, 2008 | Jerini AG (FSE:JI4) announced today the signing of a research collaboration agreement with Baxter AG to develop a novel synthetic molecule for use in affinity purification of a therapeutic protein. Under the terms of the agreement, Jerini will use its Peptides-to-Drugs (P2D) technology platform to identify and develop a specific binding molecule for protein purification, which potentially offers key advantages over conventional antibody-assisted protein purification.
“We are very pleased to announce our fourth collaboration agreement with Baxter. Jerini’s proprietary P2D technology platform offers a unique and highly effective approach in the development of novel peptidomimetics or small molecules with applications in protein purification as well as drug development,” said Jens Schneider-Mergener, Chief Executive Officer at Jerini.
Under the terms of the agreement, Jerini will receive an upfront payment and full time equivalents (FTE) funding along with potential milestone payments for the achievement of discovery, preclinical, and clinical goals and royalties on eventual product sales.
About Jerini AG
Jerini is a pharmaceutical company based in Berlin, Germany, focusing on the discovery, development, and commercialization of novel peptide-based drugs. The company pursues disease indications that have limited or no treatment options and has built a drug pipeline composed of its own programs, as well as others in collaboration with established partners. Jerini has filed marketing approval applications for its lead product, Firazyr® (Icatibant), in the treatment of hereditary angioedema, with both the European Medicines Evaluation Agency and the US Food and Drug Administration and expects regulatory decisions in the first half of 2008. Based on its technology platform, Jerini has also established several in-house development programs, which address indications within the therapeutic areas of ophthalmology, oncology, and inflammatory disease.
SOURCE: JERINI AG |
